Investors' speedy study hopes quashed as Novo Nordisk continues cardiovascular trial
![Photo: Novo Nordisk / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article14280933.ece/ALTERNATES/schema-16_9/doc7m5cao9adtibdwqe8yn.jpg)
Novo Nordisk has decided to keep a large-scale study investigating the cardiovascular benefits of obesity drug Wegovy (semaglutide) running, which could be to the chagrin of investors who hoped for results sooner rather than later.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.